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Chemotherapy and radiotherapy for breast cancer may lead to cardiac dysfunction, but 
the prevalence of long-term echocardiographic evidence of cardiac dysfunction is 
unknown among survivors. 
 
Patients and methods  
In a cross-sectional study in primary care, we included 350 women who survived breast 
cancer for at least five years after diagnosis (treated with chemotherapy and/or 
radiotherapy) and 350 matched women (age and primary care physician). The primary 
outcome was cardiac dysfunction, defined as a left ventricular (LV) ejection fraction 
<54% and an age-corrected decreased LV diastolic function. Secondary outcomes 




Median age at diagnosis was 63 (IQR 57–68) years for the breast cancer survivors. 
Median follow-up after diagnosis was 10 (IQR 7–14) years. LV ejection fraction <54% 
was present in 52 (15.3%) survivors and 24 (7%) controls (OR 2.4, 95%CI 1.4–4.0), but 
there was no significant increased prevalence of either LV ejection fraction <50% or LV 
diastolic dysfunction. Serum NT-proBNP levels were increased, cardiovascular disease 
was more frequently diagnosed, and cardiovascular medication use was more frequent 
among survivors compared with controls. These associations remained after 
adjustment for relevant covariates at diagnosis and at follow-up. 
 
Conclusion  
In the long term, breast cancer survivors are at increased risk of mild LV systolic 
dysfunction, increased NT-proBNP levels, and cardiovascular disease compared with 
matched controls, even after adjustment for cardiovascular risk factors. Previous breast 
cancer treatment with chemotherapy, radiotherapy, or both should be considered 
when assessing a patient’s cardiovascular risk profile. 
  
141080-Boerman_BNW.indd   36 08-01-20   08:48
Long-term follow-up cardiac dysfunction 
 
 
                                                                                                                                                                                           



















Breast cancer is the most common cancer among women, with approximately 0.5 
million women affected annually in Europe.2, 96 Courtesy of screening programs and 
advances in cancer treatment, the 5-year overall survival rates have increased to 85%12. 
Although adjuvant therapies like anthracycline-based chemotherapy, trastuzumab, and 
radiotherapy are very effective, they may cause cardiac dysfunction decades after 
treatment.32 This late cardiac dysfunction can remain subclinical because of its gradual 
onset and presentation with vague symptoms. Since the prevalence of subclinical 
cardiac dysfunction is unknown among long-term survivors of breast cancer, and no 
interventions have been established to manage it, there are no specific follow-up 
recommendations. Timely diagnosis of cardiac dysfunction is important because early 
treatment of associated risk factors may prevent further deterioration and improve 
prognosis.97 
 Previous long-term studies among adult female breast cancer survivors have 
focused on the frequency of only diagnosed cardiac dysfunction, which may have 
underestimated the prevalence of cardiac dysfunction.32-37 By contrast, studies in 
selected hospital populations may have overestimated the prevalence of cardiac 
dysfunction in these women.28-31 This is exacerbated by the lack of controlled long-term 
studies assessing the incidence of undiagnosed cardiac dysfunction in adult female 
breast cancer survivors with echocardiographic data in non-hospital settings.41 
Therefore, we assessed the prevalence of long-term echocardiographic-based cardiac 
dysfunction among breast cancer survivors treated with chemotherapy (± 
radiotherapy) or radiotherapy only, and compared that with the prevalence of cardiac 












We performed a cross-sectional, population-based study to assess the frequency of 
cardiac dysfunction in a primary care setting. All inhabitants of the Netherlands are 
enlisted in a electronical record of a primary care physician (PCP), who registers 
everything according to International Classification of Primary Care (ICPC)85 and 
Anatomical Therapeutic Chemical (ATC) classification codes.98  
Relevant data were retrieved from patients’ medical records at primary care practices 
and were entered into a separate, anonymous, password-protected database. In 
practices contributing to data registries, we were able to retrieve information from 
non-respondents. The medical ethics committee of the University Medical Center 
Groningen (UMCG) approved this study, and all participants gave written informed 
consent. The study was also registered at clinicaltrials.gov [ID:NCT01904331]. 
 
Participants 
Women were considered breast cancer survivors if they were diagnosed with breast 
cancer stage I –III, had been free of disease for at least five years, and were included 
from the electronic patient records of 80 PCPs in the north of the Netherlands. When 
women had been diagnosed with a local/loco-regional recurrence of breast cancer, 
they were included if they had been free of disease for at least five years. The inclusion 
criteria were treatment for breast cancer with chemotherapy, radiotherapy, or both. 
The exclusion criteria were metastatic disease at time of breast cancer diagnosis, breast 
cancer treatment after 80 years of age, and treatment for other types of cancer. For 
each included survivor, a randomly selected control was invited from the same PCP, 
from the same age (± one year), but without a history of cancer or cancer treatment 
(chemotherapy or radiotherapy). We excluded women with severe mental or physical 
illness from both groups when they were not able to come to the university hospital 
according to their PCP. Compliance with the inclusion and exclusion criteria was 
checked using the electronic patient records and checked with the PCP.  
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Box 1 Overview of data derived from the electronic patient files of primary care physicians  
 
Assessments and procedures 
For all women, we collected data based on the ICPC codes for cardiovascular (CV) risk 
factors and CV disease (CVD), and used the ATC prescription codes for CV medications 
(Box 1). Hospital charts from breast cancer survivors were reviewed for detailed 
information on breast cancer treatment, including administered chemotherapy 
regimens, cumulative dosages, anti-hormone treatments, and radiotherapy site. In 
general, radiotherapy in the Netherlands consisted of Linac based photon tangential 
fields up to a dose of 50 Gy with or without a boost.99 
We performed the following procedures at a cross-sectional follow-up assessment. 
Echocardiography was performed by experienced UMCG staff, using a VIVID E9 
ultrasound machine (GE, Horten, Norway) according to the guidelines of the European 
Association of Echocardiography100, 101. A prespecified imaging protocol was used and 
images were digitally stored. We also performed electrocardiography (ECG) and 
obtained plasma in lithium-heparin stored at -80oC for batch analysis of N-terminal pro 
B-type natriuretic peptide (NT-proBNP). Finally, we assessed body mass index (BMI) by 
ICPC codes comprising of the presence of CV risk factors 
 dyslipidaemia [ICPC: T93] 
 hypertension [ICPC: K86 AND K87] 
 diabetes mellitus [ICPC: T90] 
ICPC codes comprising the presence of CVD 
 Heart failure 
 acute and chronic congestive heart failure [ICPC: K77] 
 Ischemic cardiac disease 
 stable/unstable angina pectoris [ICPC: K74] 
 acute myocardial infarction [ICPC: K75] 
 coronary artery sclerosis [ICPC: K91) 
 transient ischemic attack [ICPC: K89] 
 cerebrovascular accident [ICPC: K90]) 
 Atrial fibrillation 
 atrial fibrillation [ICPC: K78] 
 Other 
 paroxysmal tachycardia [ICPC: K79] 
 non-rheumatic valve disease [ICPC: K83] 
 Wolff–Parkinson–White syndrome, atrioventricular block, 
cardiomyopathy, and long QT-syndrome [ICPC: K84] 
 











measuring weight and length, smoking status (self-reported), and responses to the 




The primary outcomes were left ventricular (LV) systolic and diastolic dysfunction. LV 
systolic cardiac dysfunction was defined as a LV ejection fraction (LVEF) <54% according 
to the European Association for Cardio Vascular Imaging/American Society of 
Echocardiography (EACVI/ASE), measured by the biplane method of disks summation 
(modified Simpson’s rule).100 If image quality was too low to detect the endocardial 
border reliably, an estimation of the LVEF was given. LV diastolic cardiac dysfunction 
was defined as e’ lateral or e’ septal at 2.5% below the normal range for each age group, 
according to the EACVI/ASE recommendations. When impaired relaxation was present 
dysfunction was considered severe.101 
 The main secondary outcomes were: clinically used LVEF cut-off points <45% 
and <50%, right ventricular systolic dysfunction, valve dysfunction (at least II/III 
insufficiency of any valve), any ECG abnormality, and increased NT-proBNP (>125 
ng/ml)103. Right ventricular (RV) systolic function was measured through the tricuspid 
annular plane systolic excursion (< 17 mm) and tricuspid lateral annular systolic velocity 
wave (<9.5 cm/s) by Doppler imaging.100 Other secondary outcomes were newly 
diagnosed CVD and CV medication. 
Power analysis 
In the primary comparison, breast cancer survivors were compared with controls. 
Based on an event rate of 25% for cardiac dysfunction104-106, a 5% type I error rate, a 
20% type II error rate, and an anticipated difference of 6.25% (odds ratio [OR] 2.25) 
between survivors and controls in the proportion of cases with cardiac dysfunction, we 
calculated a sample size of 350 participants per group. 
Statistics 
Baseline characteristics were described at the date of diagnosis or at the corresponding 
index date for the matched controls. Age and follow-up period were reported as 
medians and interquartile ranges (IQR). Information on diagnosis and treatment was 
presented for survivors. 
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 Besides comparing all survivors with all controls on all outcomes, we also 
specifically compared the chemotherapy ± radiotherapy group with the chemotherapy 
control group and the radiotherapy only group with the radiotherapy control group. 
Logistic regression analysis was used to compare the prevalence of long-term cardiac 
dysfunction and secondary outcomes between survivors and controls by estimating 
ORs and their 95% confidence intervals (95%CIs). To evaluate whether the association 
between breast cancer treatment and the prevalence of long-term cardiac dysfunction 
was confounded by risk factors, multivariable logistic regression was performed to give 
an adjusted OR for LV dysfunction, increased NT-proBNP, and the occurrence of CVD 
after breast cancer diagnosis. We adjusted for baseline characteristics (model 1) and 
for characteristics at the time of echocardiography (model 2). The effect of higher-dose 
anthracycline therapy (e.g., doxorubicin dose > 240 mg/m2 or epirubicin dose > 450 
mg/m2) compared with low-dose therapy, and the effect of left-sided radiotherapy 
compared with right-sided therapy, were also analysed. Finally, we compared the ages 
and CVD diagnoses of participants and non-participants from PCPs that contributed to 
data registries. To evaluate the impact of potential selection bias on the prevalence of 
diagnosed CVD, a sensitivity analysis was performed including all eligible women who 
were invited. All analyses were performed with IBM SPSS, Version 23. 
  
3




Among 741 breast cancer survivors considered eligible by 80 participating PCPs, 668 
were approached for inclusion (Figure 1). There were 22 women with a local/loco-
regional recurrence in our sample. The median year of diagnosis was 2004 (IQR 2000-
2007). Compared with non-participants from 58 PCPs, participating survivors tended to 
be four years younger (p<0.01), and participating controls tended to be two years 
younger (p<0.01). Participating survivors showed no differences with regards to the 
prevalence of diagnosed CVD, but fewer participating controls had CVD (OR 0.5 [95%CI 
0.3-0.8]), probably based on ischemic CVD (OR 0.3 [95%CI 0.3-0.6]; Table 1). In the 
sensitivity analysis including all eligible women, we observed no difference in 
diagnosed CVD, except for atrial fibrillation, which was more frequent in survivors 
(Table 2).
Figure 1 Flow diagram of the selection of survivors of breast cancer and their matched controls
After exclusion by PCP 







Subjects identified and meeting in- and exclusion criteria 
Breast cancer survivors (N=741) and controls (N=1524)
General practitioner (GP)
(N=80)
Reasons for exclusion by GP
Physical: survivors (N=13) and 
controls (N=27) 
Psychosocial: survivors (N=20) and 
controls (N=48)
Other: survivors (N=40) and 
controls (N=84)
Not invited
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Table 1 Characteristics and the presence of CVD of eligible breast cancer patients (N = 413) and eligible controls (N = 
579) who were invited to participate: participants versus non-participants * 
 
Eligible breast cancer 
patients 
(N = 413) 
 Eligible controls (N = 579)  
 Participant 
(N = 292) 
Non-
participant 
(N = 151) 
 Participant 
(N = 292) 
Non-
participant 
(N = 322) 
 
















(6–14) P 0.992 – –  
 N (%) N (%) OR (95%CI) N (%) N (%) OR (95%CI) 
Diagnosed CVD 47 (16.1) 24 (15.9) 1.0(0.6 - 1.7) 26 (8.9) 54 (16.8) 0.5(0.3 - 0.8) 
Heart failure  3 (1.0) 1 (0.7) 1.6(0.2 - 15.1) 2 (0.7) 4 (1.2) 0.6(0.1 - 3.0) 
Ischemic CVD a 26 (8.9) 15 (9.9) 0.9(0.5 - 1.7) 11 (3.8) 38 (11.8) 0.3(0.2 - 0.6) 
Atrial 
fibrillation 11 (3.8) 9 (6.0) 0.6(0.3 - 1.5) 5 (1.7) 8 (2.5) 0.7(0.2 - 2.1) 
Other CVD b 16 (5.5) 7 (4.6) 1.2(0.5 - 3.0) 11 (3.8) 14 (4.3) 0.9(0.4 - 1.9) 
(*) Data are based on patient files of 58 (out of 80) PCPs contributing to data registries;  
( ) Tested with t-test;  
(a) Stable and unstable angina pectoris, coronary sclerosis, acute myocardial infarction, transient ischemic attack, 
cerebrovascular accident;  
(b) Paroxysmal tachycardia (supraventricular and ventricular), non-rheumatic valve dysfunction, Wolff–Parkinson–
White syndrome, atrioventricular block, cardiomyopathy, long QT-syndrome. 
 
 
Table 2 Sensitivity analysis: comparison of the prevalence of CVD at time of cross-sectional assessment between all 
invited eligible northern Dutch breast cancer survivors (N=443) and all invited eligible controls (N=614)* 
 
Eligible breast cancer 
survivors 
(N = 443 ) 
Eligible controls 
 
(N = 614) 
 
 
 N (%) N (%) OR (95% CI) Age-ajusted OR (95%CI) 
Prevalence of CVD 71 (16.0) 80 (13.0) 1.3 (0.9-1.8) 1.4 (0.9-2.0) 
Heart failure 4 (0.9) 6 (1.0) 0.9 (0.3-3.3) 1.0 (0.3-3.7) 
Ischemic CVD a 41 (9.3) 49 (8.0) 1.2 (0.8-1.8) 1.2 (0.8-1.9) 
Atrial fibrillation 20 (4.5) 13 (2.1) 2.2 (1.1-4.4) 2.5 (1.2-5.2) 
Other cardiac diseases b 23 (5.2) 25 (4.1) 1.3 (0.7-2.3) 1.3 (0.7-2.4) 
(*) Data are based on patient files of 58 (out of 80) PCPs contributing to data registries; (a) Stable and unstable 
angina pectoris, coronary sclerosis, acute myocardial infarction, transient ischemic attack, cerebrovascular accident; 
(b) Paroxysmal tachycardia (supraventricular and ventricular), non-rheumatic valve dysfunction, Wolff–Parkinson–









At diagnosis, women in the chemotherapy ± radiotherapy group had a median age of 
49 compared with 54 years in the radiotherapy only group (Table 3). In the 
chemotherapy ± radiotherapy group, 81.1% were treated with anthracyclines 
(doxorubicin [n = 53] or epirubicin [n = 89]), and 68.6% received additional 
radiotherapy. The median cumulative anthracycline dose (doxorubicin isotoxic dose) 
was 238 mg/m2, and no patient received a real high-dose doxorubicin (>400 mg/m2) 
or epirubicin (>900 mg/m2) (Table 4)107. Of the survivors 97% was irradiated after 1990.  
At diagnosis, the rates of dyslipidaemia, hypertension, diabetes, diagnosed CVD, and 
use of CV medication were not statistically different between the chemotherapy ± 
radiotherapy group, the radiotherapy only group, and their respective controls (Table 
3). 
 
Table 3 Baseline characteristics at time of breast cancer diagnosis of survivors treated with chemotherapy ± 

















(N = 175) 
Age at breast cancer 
diagnosis or index age for 
matched control; years, 
median (IQR) 
49 (42–54) 49 (42–55) 54 (49–59) 53 (48–58) 
 N (%) N (%) N (%) N (%) 
Risk factors for CVD 20 (11.4) 18(10.3) 25 (14.3) 32 (18.3) 
Dyslipidemia 7 (4.0) 8 (4.6) 5 (2.9) 11 (6.3) 
Hypertension 17 (9.7) 13 (7.4) 19 (10.9) 27 (15.4) 
Diabetes mellitus 2 (1.1) 2 (1.1) 8 (4.6) 3 (1.7) 
Diagnosed CVD  5 (2.9) 2 (1.1) 3 (1.7) 5 (2.9) 
Heart failure 0 (0) 0 (0) 0 (0) 0 (0) 
Ischemic heart disease a 3 (1.7) 1 (0.6) 2 (1.1) 0 (0) 
Atrial fibrillation 0 (0) 0 (0) 1 (0.6) 2 (1.1) 
Other heart diseases b 2 (1.1) 1 (0.6) 1 (0.6) 3 (1.7) 
Cardiovascular medication 14 (8.0) 10 (5.7) 15 (8.6) 10 (5.7) 
ACE-inhibitor 5 (2.9) 2 (1.1) 8 (4.6) 5 (2.9) 
Antiplatelet agents 3 (1.7) 0 (0) 4 (2.3) 0 (0) 
Beta-blockers 5 (2.9) 3 (1.7) 4 (2.3) 3 (1.7) 
Diuretics 6 (3.4) 4 (2.3) 6 (3.4) 2 (1.1) 
Statins 3 (1.7) 3 (1.7) 5 (2.9) 1 (0.6) 
(*) There were no statistical significant differences between groups, tested with Chi-square test; 
(a) Stable and unstable angina pectoris, coronary sclerosis, acute myocardial infarction, transient ischemic attack, 
cerebrovascular accident;  
(b) Paroxysmal tachycardia (supraventricular and ventricular), non-rheumatic valve dysfunction, Wolff–Parkinson–
White syndrome, atrioventricular block, cardiomyopathy, long QT-syndrome. 
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Table 4 Detailed characteristics of breast cancer diagnosis and treatment for the patients treated with chemotherapy 
± radiotherapy (N = 175) and radiotherapy only (N = 175) 
 Chemotherapy ± radiotherapy (N = 175) 
Radiotherapy 
(N = 175) 
 N (%) N (%) 
T-size    DCIS 3 (1.7) 18 (10.3) 
   T1 40 (41.1) 118 (67.4) 
   T2 80 (45.7) 27 (15.4) 
   T3 10 (5.7) 1 (0.6) 
   T4 3 (1.7) 0 (0) 
   Unknown 7 (4.0) 11 (6.3) 
Lymph node involvement  N0 56 (32.0) 131 (74.9) 
   N1 95 (54.3) 23 (13.1) 
   N2 12 (6.9) 3 (1.7) 
   N3 6 (3.4) 0 (0) 
   Unknown 6 (3.4) 18 (10.3) 
Type of chemotherapy* CMF 30 (17.1) – 
   AC 47 (26.9) – 
   FEC 67 (38.3) – 
   AC + T 5 (2.9) – 
   FEC + T 21 (12.0) – 
   Other  3 (1.8) – 
   Unknown** 2 (1.1) – 
 Median (IQR) Median (IQR) 
Cumulative dose epirubicin (mg/m2) a 444.4 (300–450) – 
Cumulative dose doxorubicin (mg/m2) b 240 (235–240) – 
Cumulative anthracycline dose; mg/m2, median 
(IQR) *** 238 (228–240) – 
 N (%) N (%) 
Trastuzumab 13 (7.4) – 
Anti-hormonal therapy 110 (62.9) 41 (23.4) 
Tamoxifen  24 (21.8) 11 (26.8) 
Aromatase-inhibitors  14 (12.7) 4 (9.8) 
Tamoxifen followed by aromatase-inhibitors 62 (56.4) 23 (56.1) 
Other 9 (8.2) 2 (4.9) 
Unknown 1 (0.9) 1 (2.4) 
Radiotherapy 120 (68.6%) 175 (100) 
Side: bilateral or left 84 (48.0) 89 (51.5) 
 
(*) C = cyclophosphamide; M = methotrexate; F = 5-fluorouracil; A = doxorubicin; E = epirubicin; T = taxanes; 
(**) Other consisted of 1 patients with CMF and FEC, 1 with M and F, and 1 with M, F, A, ans vincristine;  
(***) Doxorubicin isotoxic dose, information available for 108 patients (76%); 
 
(a) This information was retrieved for 72 out 89 patients who received epirubicin; 











Findings at the cross-sectional assessment 
The median follow-up after breast cancer diagnosis was 10 years (Table 4), at which 
point the breast cancer survivors did not differ significantly from their controls in terms 
of CV risk factors (Table 5). 
 Compared with controls, survivors had a significantly increased risk of an 
LVEF <54% (OR 2.4 [95%CI 1.4-4.0]), and there was a similar but non-significant trend 
for the risk of an LVEF <50% (OR 1.7 [95%CI 0.7-4.0]); however, few women had an LVEF 
<45% (n=4; Table 4). In addition, prevalence rates for LV diastolic dysfunction were also 
higher among survivors than among controls, but not statistically significant (OR 1.2 
[95%CI 0.9-1.6]; Table 4). Few women had severe diastolic dysfunction (17 survivors vs 
12 controls). 
 Compared with controls, prevalence rates were higher among survivors for 
increased NT-proBNP levels (OR 1.5 [95%CI 1.1-2.1]), newly diagnosed CVD (OR 2.0 
[95%CI 1.2-3.3]), and prescribed CV medication (OR 1.4 [95%CI 1.0-2.0]). Concerning 
CVD diagnoses, there was an increased likelihood of ischemic CVD, with angiotensin-
converting-enzyme inhibitors, antiplatelet agents, and beta-blockers being prescribed 
more frequently. However, there were no significant differences between survivors 
and controls on other outcomes. 
 There was a significantly increased risk of LV systolic dysfunction (LVEF <54%) 
in the chemotherapy ± radiotherapy group compared with their controls (OR 2.5 [95%CI 
1.2-5.4]; Table 6). This treatment group also had a more than two-fold increased risk of 
being diagnosed with CVD (OR 2.3 [95%CI 1.0-4.9]), which was mainly attributable to 
ischemic CVD. Angiotensin-converting enzyme inhibitors and antiplatelet agents were 
prescribed significantly more often among survivors than controls (Table 4). Concerning 
anthracycline treatment, we found the same increased risk for LV systolic dysfunction 
as in the other groups (Table A.5). No differences were found between higher versus 
low-dose anthracycline-treated patients. 
 Radiotherapy only was also associated with an increased risk of LV systolic 
dysfunction (LVEF < 54%; OR 2.3 [95%CI 1.1-4.6]) and raised NT-proBNP level (OR 1.6 
[95%CI 1.0-2.4]); however, there was no significant increased risk of CVD in the 
radiotherapy group (Table 6). We found no significant differences in LV function 
between left-sided and right-sided radiotherapy, either before or after excluding those 
who received chemotherapy (Table 6). However, in patients treated with left-sided 
therapy NT-proBNP level was raised (OR1.6 ([95%CI 1.0–2.6]). 
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(N = 350) 
 
 
Follow-up duration; years, median (IQR)  10 (7–14) 10 (8–14)  





63 (57–68)  
Cardiac function N (%) N (%) OR (95%CI) 
Left ventricular dysfunction     
Systolic dysfunction a    
LVEF < 54% 
LVEF < 50% 







2.4 (1.4 - 4.0) 
1.7 (0.7 - 4.0) 
1.0 (0.1 - 7.2) 
Diastolic dysfunction b  147 (43.4) 133 (39.5) 1.2 (0.9 - 1.6) 
2 c 17 (5.5) 12 (3.9) 1.4 (0.7 - 3.0) 











0.7 (0.2 - 2.4) 
0.8 (0.3 - 2.2) 
Valve dysfunction d 3 (0.9) 5 (1.4) 0.6 (0.4 - 2.5) 
Any abnormality on ECG  83 (24.1) 68 (19.7) 1.3 (0.9 - 1.9) 
Increased NT-proBNP e 125 (36) 95 (27.1) 1.5 (1.1 - 2.1) 
Risk factors for CVD, newly diagnosed CVD, and use of cardiovascular medication at time of echocardiography 
as registered in PCP files 
Risk factors for CVD - any 139 (39.7) 135 (38.6) 1.0 (0.8 - 1.4) 
Dyslipidemia 54 (15.4) 58 (16.6) 0.9 (0.6 - 1.3) 
Hypertension 108 (30.9) 106 (30.3) 1.0 (0.7 - 1.4) 
Diabetes mellitus 29 (8.3) 16 (4.6) 1.9 (0.99 - 3.5) 
Diagnosed CVD 49 (14.0) 26 (7.4) 2.0 (1.2 - 3.3) 
Heart failure 1 (0.3) 3 (0.9) 0.3 (0.03 - 3.2) 
Ischemic cardiovascular diseases f 26 (7.4) 13 (3.7) 2.1 (1.1 - 4.1) 
Atrial fibrillation 11 (3.1) 4 (1.1) 2.8(0.9 - 8.9) 
Other cardiac diseases g 20 (5.7) 9 (2.6) 2.3 (1.0 - 5.1) 
Cardiovascular medication 132 (37.7) 104 (29.7) 1.4 (1.0 - 2.0) 
ACE-inhibitor 65 (18.6) 42 (12.0) 1.7 (1.1 - 2.5) 
Antiplatelet agents 29 (8.3) 12 (3.4) 2.5 (1.3 - 5.1) 
Beta-blockers 54 (15.4) 34 (9.7) 1.7 (1.1 - 2.7) 
Diuretics 33 (9.4) 39 (11.1) 0.8 (0.5 - 1.4) 
Statins 54 (15.4) 40 (11.4) 1.4 (0.9 - 2.2) 
(a) Measured by Simpson’s biplane (61.8%) or BiPQ/estimate (38.2%), not available for women with atrial fibrillation 
during measurement (N = 6) and women with immeasurable LVEF (N = 14); 
(b) Decreased e’ lat or e’ sept, not available for women with atrial fibrillation during measurement (N = 6), valve 
replacement (N = 4) and women with immeasurable e’ lat and e’ sept (N = 14); 
(c) Not available for women with atrial fibrillation during measurement (N = 6), valve replacement (N = 4), and women 
with immeasurable e’ lat and e’ sept (N = 14); 
(d) Minimal II/III valve dysfunction from one of the 4 cardiac valves; 
(e) Not available for 3 women; 
(f) Stable and unstable angina pectoris, coronary sclerosis, acute myocardial infarction, transient ischemic attack, 
cerebrovascular accident; 
(g) Paroxysmal tachycardia (supraventricular and ventricular), non-rheumatic valve dysfunction, Wolff–Parkinson–
White syndrome, atrioventricular block, cardiomyopathy, long QT-syndrome.
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Table 6 Characteristics at time of echocardiography of survivors treated with chemotherapy ± radiotherapy (N = 175) 






























Cardiovascular risk factors in GP files 
dyslipidemia 14 (8.0) 20 (11.4) 0.7 (0.3 - 1.4) 28 (16.0) 19 (10.9) 1.6 (0.8 - 2.9) 
Hypertension 29 (16.6) 29 (16.6) 1.0 (0.6 - 1.8) 43 (24.6) 37 (21.1) 1.2 (0.7 - 2.0) 
Diabetes 8 (4.6) 5 (2.9) 1.6 (0.5 - 5.1) 13 (7.4) 6 (3.4) 2.3 (0.8 - 6.1) 
Measurements at time of echocardiography 
BMI above 25 
kg/m2 
100 (57.1) 89 (50.9) 1.3 (0.8 - 2.0) 99 (56.6) 113 (64.6) 0.7 (0.5 - 1.1) 
Physical fit a 134 (76.6) 139(79.4) 0.8 (0.5 - 1.4) 128 (73.6) 142 (82.1) 0.6 (0.4 - 1.0) 
Current smokers  33 (18.9) 29 (16.6) 1.2 (0.7 - 2.0) 32 (18.4) 24 (13.7) 1.4 (0.8 - 2.5) 
BMI above 25 
kg/m2 
100 (57.1) 89 (50.9) 1.3 (0.8 - 2.0) 28 (16.0) 19 (10.9) 1.6 (0.8 - 2.9) 
minutes, SQUASH questionnaire). 
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median (IQR) 10 (7–13) 10 (8–14)  10 (8–15) 10 (7–15)  
Age at assessment; 
yr, median (IQR) 60 (53–66) 60 (53–66)  65 (61–70) 66 (61–70)  
 N (%) N (%) OR (95%CI) N (%) N(%) OR (95%CI) 
LV dysfuntion        
Systolica       
 LVEF<54% 25 (14.8) 11 (6.4) 2.5 (1.2 - 5.4) 27 (15.9) 13 (7.7) 2.3 (1.1 - 4.6) 
LVEF < 50% 7 (4.1) 5 (2.9) 1.4 (0.4 - 4.6) 8 (4.7) 4 (2.4) 2.1 (0.6 - 6.9) 
LVEF < 45% 1 (0.6) 0 (0) - 1 (0.6) 2 (1.2) - 
Diastolicb 79 (46.7) 65 (38.7) 1.4 (0.9 - 2.1) 68 (40.0) 68 (40.2) 1.0 (0.6 - 1.5) 
Diastolic with LAVI 
2 c 10 (6.6) 6 (4.0) 1.7 (0.6 - 4.7) 7 (4.4) 6 (3.8) 1.2 (0.4 - 3.5) 
RV systolic dysfunction      
Decreased TAPSE 2 (1.2) 3 (1.8) 0.7 (0.1 - 4.1) 2 (1.2) 3 (1.8) 0.7 (0.1 - 4.1) 
 4 (2.5) 6 (3.6) 0.7 (0.2 - 2.5) 3 (1.9) 3 (1.9) 1.0 (0.2 - 5.0) 
Valve dysfunction 1 (0.6) 3 (1.7) 0.3 (0.03 - 3.2) 2 (1.1) 2 (1.1) 1.0 (0.1 - 7.2) 
ECG abnormalities 39 (22.7) 36 (20.8) 1.1 (0.7 - 1.9) 48 (27.9) 41 (23.8) 1.2 (0.8 - 2.0) 
Increased NT-
proBNPe 56 (32.7) 44 (25.1) 1.5 (0.9 - 2.3) 68 (39.1) 51 (29.1) 1.6 (1.0 - 2.4) 
Diagnosed CVD 21 (12.0) 10 (5.7) 2.3 (1.0 - 4.9) 28 (16.0) 16 (9.1) 1.9 (0.98 - 3.6) 
Heart failure 1 (0.6) 1 (0.6) 1.0 (0.06 - 16) 0 (0) 2 (1.1) - 
Ischemic CVD f 12 (6.9) 7 (4.0) 1.8 (0.7 - 4.6) 14 (8.0) 6 (3.4) 2.4 (0.9 - 6.5) 
Atrial 
fibrillation 4 (2.3) 1 (0.6) 
4.1 (0.5 - 
36.8) 7 (4.0) 3 (1.7) 2.4 (0.6 - 9.4) 
Other CD g 7 (4.0) 3 (1.7) 2.4 (0.6 - 9.4) 13 (7.4) 6 (3.4) 2.3 (0.8 - 6.1) 
Cardiovascular 
medication 57 (32.6) 44 (25.1) 1.4 (0.9 - 2.3) 75 (42.9) 60 (34.3) 1.4 (0.9 - 2.2) 
ACE-inhibitor 39 (22.3) 21 (12.0) 2.1 (1.2 - 3.8) 40 (22.9) 29 (16.6) 1.5 (0.9 - 2.5) 
Antiplatelets 16 (9.1) 6 (3.4) 2.8 (1.1 - 7.4) 13 (7.4) 6 (3.4) 2.3 (0.8 - 6.1) 
Beta-blockers 26 (14.9) 17 (9.7) 1.6 (0.8 - 3.1) 37 (21.1) 24 (13.7) 1.7 (0.96 - 3.0) 
Diuretics 19 (10.9) 16 (9.1) 1.2 (0.6 - 2.4) 26 (14.9) 29 (16.6) 0.9 (0.5 - 1.6) 
Statins 26 (14.9) 16 (9.1) 1.7 (0.9 - 3.4) 35 (20.0) 28 (16.0) 1.3 (0.8 - 2.3) 
 
(a) Measured by Simpson’s biplane (61.8%) or BiPQ/estimate (38.2%), not available for women with atrial fibrillation 
during measurement (N = 6) and women with immeasurable LVEF (N = 14); 
(b) Decreased e’ lat or e’ sept, not available for women with atrial fibrillation during measurement (N = 6), valve 
replacement (N = 4), and women with immeasurable e’ lat and e’ sept (N = 14); 
(c) Not available for women with atrial fibrillation during measurement (N = 6), valve replacement (N = 4) and women 
with immeasurable e’ lat and e’ sept (N = 14); 
(d) Minimal II/III valve dysfunction from one of the 4 cardiac valves; 
(e) cut- Not available for 3 women; 
(f) Stable and unstable angina pectoris, coronary sclerosis, acute myocardial infarction, transient ischemic attack, 
cerebrovascular accident; 
(g) Paroxysmal tachycardia (supraventricular and ventricular), non-rheumatic valve dysfunction, Wolff–Parkinson–
White syndrome, atrioventricular block, cardiomyopathy, long QT-syndrome. 
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Table 8 Outcomes of breast cancer patients treated with anthracyclines based (N = 142) compared to their controls 
(N = 142) 
 





(N = 142) 
Controls 
 
(N = 142)  Higher dose f 
(N = 21) 
Low-dose f 
(N = 87) 
 
Follow-up; yr, 
 9 (7–12) 9 (7–12)  9 (7–12) 8 (7–12)  
Age at echo; yr, 
 59 (53–66) 60 (53–66)  61 (52–64) 60 (53–66)  
 N (%) N (%) OR (95%CI) N (%) N (%) OR (95%CI) 
Radiotherapy 98 (69.0) – - 15 (71.4) 64 (73.6) - 
LV dysfunction       
LVEF <54% 22 (16.2) 11 (7.9) 2.2 (1.0 - 4.8) 1 (4.8) 16 (19.8) 0.2(0.03 - 1.6) 
LVEF<50% 7 (5.1) 5 (3.6) 1.5 (0.5 - 4.7) 0 (0) 6 (7.4) – 
LVEF<45% 0 (0) 1 (0.7) – 0 (0) 0 (0) – 
Diastolic dysf.a  62 (45.3) 51 (37.2) 1.4 (0.9 - 2.3) 8 (38.1) 41 (50.0) 0.6 (0.2 - 1.6) 
Diastolic dysf + 
LAVI 
b 
9 (7.2) 5 (4.1) 1.8 (0.6 - 5.5) 1 (5.3) 7 (9.5) 0.5(0.06 - 4.6) 
RV dysfunction       
Decr.TAPSE 1 (0.8) 1 (0.7) 1.0(0.1 - 16.6) 0 (0) 0 (0) – 
Decr. S’ 3 (2.4) 5 (3.7) 0.6(0.1 - 2.7) 0 (0) 2 (2.6) – 
Valve dysf. 1 (0.7) 2 (1.4) 0.5(0.04 - 5.5) 0 (0) 0 (0)  
Abnormal ECG 31 (22.3) 29 (20.7) 1.1(0.6 - 1.9) 5 (25.0) 19 (22.4) 1.2 (0.4 - 3.6) 
Incr. NT-pro BNP 47 (33.6) 35 (24.6) 1.5(0.9 - 2.6) 7 (36.8) 25 (28.7) 1.5 (0.5 - 4.1) 
(a) Measured by Simpson’s biplane (72.5%) or BiPQ/estimate (28.5%), not available for women with atrial fibrillation (N 
= 2) during measurement and women with immeasurable LVEF (n = 5); 
(b) Not available for women with atrial fibrillation (N = 2) during measurement, valve replacement (N = 0) and women 
with immeasurable e’ lat and e’ sept (N = 7); 
(c) Minimal II/III valve dysfunction from one of the 4 cardiac valves; 
(e) Not available for 2 women; 
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Table 9 Outcomes of breast cancer patients who received bilateral or left-sided radiotherapy compared to patients 
who received right-sided radiotherapy: for all patients and those who received radiotherapy only* 
 
 All patients with radiotherapy  
Patients who received 


















(N = 83) 
 
Follow-up; yr, 
 10 (7–14) 10 (7–15)  10 (7–14) 10 (8–15)  
Age at echo; yr, 
 64 (58–69) 64 (57–68)  65 (61–70) 66 (61–70)  
 N (%) N (%) OR (95%CI) N (%) N (%) OR (95%CI) 
Radiotherapy       
LV dysfunction       
LVEF <54% 21 (14.3) 23 (16.7) 0.8 (0.4 - 1.6) 12 (14.0) 15 (18.3) 0.7 (0.3 - 1.7) 
LVEF<50% 5 (3.4) 10 (7.2) 0.5 (0.1 - 1.4) 3 (3.5) 5 (6.1) 0.6 (0.1 - 2.4) 
LVEF<45% 0 (0) 2 (1.4) – 0 (0) 2 (2.4) – 
Diastolic dysf.a  66 (45.2) 57 (41.0) 1.2 (0.7 - 1.9) 33 (38.4) 35 (42.7) 0.8 (0.5 - 1.5) 
Diastolic dysf + 
LAVI 
mL/m2 b 
6 (4.5) 7 (5.3) 0.8 (0.3 - 2.6) 2 (2.5) 5 (6.5) 0.4 (0.1 - 2.0) 
RV dysfunction       
Decr.TAPSE 2 (1.4) 1 (0.7) 1.9 (0.2 - 21.7) 1 (1.1) 1 (1.3) 1.0(0.1 - 15.9) 
Decr. S’ 2 (1.5) 3 (2.3) 0.6 (0.1 - 3.9) 1 (1.3) 2 (2.7) 0.5(0.04 - 5.4) 
Valve dysf. 2 (1.3) 0 (0) – 2 (2.2) 0 (0) – 
Abnormal ECG 40 (26.8) 33 (23.6) 1.2 (0.7 - 2.0) 24 (27.3) 23 (27.7) 1.0 (0.5 - 1.9) 
Incr. NT-pro 
BNP 65 (43.0) 45 (32.4) 1.6(0.98 - 2.6) 40 (44.4) 28 (34.1) 1.5 (0.8 - 2.9) 
( ) For 2 patients this information was missing 
( ) Right-sided treated patients served as reference  
(a) Measured by Simpson’s biplane (70.1%) or BiPQ/estimate (29.9%), not available for patients with atrial fibrillation 
(N = 3) during measurement and patients with immeasurable LVEF (N = 5);  
(b) Not available for patients with atrial fibrillation (N = 3) during measurement, valve replacement (N = 2) and women 
with immeasurable e’ lat and e’ sept (N = 3);  
(c) Minimal II/III valve dysfunction from one of the 4 cardiac valves; 









Adjustment for CV risk factors at breast cancer diagnosis (Model 1) and at cross-
sectional assessment (Model 2), did not substantially affect the ORs for the occurrence 
of LV systolic dysfunction (LVEF < 54%), increased NT-proBNP (cut- 125 pg/mL), or 
newly diagnosed CVD among survivors (Table 9). 
 
Table 10 Multivariate models, unadjusted and adjusted for measurements at time of breast cancer diagnosis (model 
1) and at follow-up echocardiography (model 2)  
 Unadjusted Adjusted model 1 a Adjusted model 2 b 
 Left ventricular systolic dysfunction (LVEF < 54%) 
All patients    
Breast cancer survivors vs. controls 2.4 (1.4 - 4.0) 2.5 (1.5 - 4.1) 2.3 (1.4 - 3.9) 
Chemotherapy ± radiotherapy    
Breast cancer survivors vs. controls 2.5 (1.2 - 5.4) 2.5 (1.2 - 5.4) 2.5 (1.2 - 5.3) 
Radiotherapy only    
Breast cancer survivors vs. controls 2.3 (1.1 - 4.6) 2.3 (1.2 - 4.8) 2.2 (1.1 - 4.4) 
 Increased NT-proBNP (Cut-  
All patients    
Breast cancer survivors vs. controls 1.5 (1.1 - 2.1) 1.5 (1.1 - 2.1) 1.5 (1.1 - 2.1) 
Chemotherapy ± radiotherapy    
Breast cancer survivors vs. controls 1.5 (0.9 - 2.3) 1.4 (0.9 - 2.3) 1.5 (0.9 - 2.4) 
Radiotherapy only    
Breast cancer survivors vs. controls 1.6 (1.0 - 2.4) 1.6 (1.0 - 2.5) 1.5 (0.9 - 2.3) 
 Newly diagnosed CVD (after baseline) 
All patients    
Breast cancer survivors vs. controls 2.0 (1.2 - 3.3) 2.1 (1.3 - 3.4) 1.9 (1.2 - 3.2) 
Chemotherapy ± radiotherapy    
Breast cancer survivors vs. controls 2.3 (1.0 - 4.9) 2.3 (1.0 - 5.0) 2.3 (1.0 - 5.1) 
Radiotherapy only    
Breast cancer survivors vs.controls 1.9 (0.98 - 3.6) 2.1 (1.1 - 4.1) 1.7 (0.9 - 3.3) 
(a) Model 1: Adjusted for measurements at baseline: cardiovascular risk factors (diabetes, hypertension, dyslipidemia), 
prior CVD and any cardiovascular medication at time of breast cancer diagnosis;  
(b) Model 2: Adjusted for measurements at time of echocardiography: cardiovascular risk factors (diabetes, 
hypertension, dyslipidemia) from PCP files, current smoking (yes/no), Body Mass Index (continuous), and physical fitness: 




LV systolic dysfunction 
In our study, the risk of mild LV systolic dysfunction (LVEF < 54%) was higher in long-
term survivors of breast cancer (15.3%) compared with age-matched controls (7.0%) 
(OR 2.4 [95% CI 1.4–4.0]). Notably, this increased risk remained after adjusting for CV 
risk factors at both breast cancer diagnosis and follow-up assessment. Two studies of 
chemotherapy-treated (± radiotherapy) breast cancer survivors reported lower 
prevalence compared to our study (14.8%), with rates of 11.5% and 5% for LV systolic 
dysfunction (LVEF <55%) over 6 years108 and 14 years30, respectively. For LVEF <50%, six 
studies reported prevalence rates varying between 1.4% and 8% over 5–14 years28, 30, 
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59, 82, 109, 110, consistent with the 4.1% found in this study. The differences between these 
studies can be explained by differences in the inclusion criteria (e.g., age) and by 
missing data for cardiac function. 
 The prevalence of systolic dysfunction among survivors treated with 
radiotherapy only was 15.9% in this study. No previous research exists, assessing LVEF 
by echocardiography among women who received radiotherapy without 
chemotherapy. When comparing survivors, who received left-sided radiotherapy with 
those who received right-sided radiotherapy, we observed no significant differences. 
This result was not in line with older studies, which did observe this left-right 
difference.49, 76, 111 A potential explanation is the use of modern radiotherapy, resulting 
in a lower heart dose, especially in left-sided breast cancer.32, 112 Of our patients 97% 
was irradiated after 1990. Unfortunately, dose distribution and mean heart dose were 
not available. In general, in the Netherlands radiotherapy for breast cancer consisted 
of conventional photon tangential fields up to 50 Gy. 
 
LV diastolic dysfunction 
We found no significant increased risk for LV diastolic dysfunction, with prevalence 
being high among both breast cancer survivors (43.4%) and controls (39.5%). This is 
similar to the data in two other studies.113, 114 In this last study, a systematic review, the 
prevalence of LV diastolic dysfunction was 36.0% (range 15.8%–52.8%) for women aged 
 60 years.114 We found no increased risk for severe LV diastolic dysfunction in breast 
cancer survivors as compared to controls. 
NT-proBNP 
NT-proBNP levels were increased more often among breast cancer survivors (36%) than 
controls (27.1%) (OR 1.5 [95%CI 1.1–2.1]). Unfortunately, the use of different assays 
precluded comparison of this prevalence with another study of breast cancer survivors 
(mean follow-up, 6 years), in which the prevalence of increased NT-proBNP was 71%.108 
In our study, patients treated with left-sided therapy had a raised NT-proBNP level 
compared to right-sided treated women. Earlier research showed that higher post-
radiotherapy NT-proBNP levels were present among women who received radiation to 
a larger heart volume.115 In the general population, it has been shown that an increased 
NT-proBNP level is predictive of cardiac mortality and heart failure.116 
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Survivors had an increased risk of CVD after diagnosis when compared with controls 
(OR 2.0 [95%CI 1.2–3.3]). Though, this risk persisted after adjusting for risk factors at 
diagnosis and follow-up, it was not found when all eligible women were included in the 
analysis, except for atrial fibrillation. Subgroup analysis showed that the higher risk 
applied to patients treated with chemotherapy ± radiotherapy. Though in our study 
numbers were small and confidence intervals were wide we found that the increased 
risk was mainly seen for ischemic cardiac diseases, whereas other studies of patients 
treated with chemotherapy have found an increased incidence of congestive heart 
failure.29, 34, 35, 37, 83 But, those studies were notable for using high-dose chemotherapy83 
or doxorubicin.29, 34, 35, 37 An increased incidence of ischemic heart disease is generally 
expected among patients treated by radiotherapy only.46 Although 69% of the 
chemotherapy-treated women in our study also received radiotherapy, it is important 
to consider that the risks of CVD after radiotherapy have declined with modern 
radiation techniques.32 
Strengths 
To our knowledge, this is the first study to compare long-term echocardiographic 
dysfunction between breast cancer survivors and controls in primary care. We used 
clear inclusion and exclusion criteria and matched the controls by age and PCP to 
guarantee a comparable socioeconomic status. This type of matching was considered 
superior to using a normal population, because it allowed for an accurate comparison. 
For survivors and controls, we obtained echocardiographic images and NT-proBNP 
levels by inviting survivors to attend a university medical centre, allowing all 
measurements to be performed using strict, standardized protocols. We also achieved 
a high participation rate (67% among survivors and 48% among controls). 
Limitations 
Some important limitations should be noted. As our study focussed on the long-term 
impact of chemotherapy and/or radiotherapy in breast cancer treatment on cardiac 
function, we included women who survived breast cancer for at least five years after 
diagnosis. Though these women might be healthier, with less cardiac disease, we 
consider this as adequate. However, for this reason, our results might underestimate 
the absolute risk of cardiac dysfunction. After selecting cases and controls, GPs 
excluded some women for several reasons and others refused participation. We 
observed that the non-participants were significantly older and that in the control 
group non-participants had more frequent CVD as compared to participating women. 
141080-Boerman_BNW.indd   54 08-01-20   08:48
Long-term follow-up cardiac dysfunction 
 
 
                                                                                                                                                                                           


















To estimate the impact of this bias by selection, a sensitivity analysis was performed on 
the relative prevalence of CVD including all eligible women. We concluded that we 
might have overestimated the impact of chemotherapy and/or radiotherapy on the 
long-term of the risk of CVD in survivors. 
Conclusion 
Among long-term survivors of breast cancer, there is an increased risk of mild LV 
systolic dysfunction and NT-proBNP elevations when compared with matched controls. 
They may also have an increased risk of newly diagnosed CVD. These increased risks 
appear to be independent of risk factors at breast cancer diagnosis and follow-up. 
However, the increased risks will not have clinical implications. In spite of this, it is 
important to enquire about previous chemotherapy or radiotherapy for breast cancer 
when assessing the CV risk profile of a patient. 
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